Attached files
file | filename |
---|---|
8-K - 8-K - SUPERNUS PHARMACEUTICALS, INC. | a12-19411_18k.htm |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Supernus to Present at Two Investor Conferences in September 2012
Rockville, MD, August 29, 2012 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the companys management will present an overview of the company at the following investor conferences in September:
Stifel Nicolaus 2012 Healthcare Conference
Location: Four Seasons Hotel, Boston, MA
Presentation date: Thursday September 6, 2012
Presentation time: 8:00 a.m. ET
Webcast: http://www.veracast.com/webcasts/stifel/healthcare2012/53201699.cfm
Rodman & Renshaw Annual Global Investment Conference
Location: The Waldorf Astoria, New York, NY
Presentation date: Monday September 10, 2012
Presentation time: 3:40 p.m. ET
Webcast: http://wsw.com/webcast/rrshq22/supn
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include Trokendi XR (extended-release topiramate), formerly known as SPN-538, and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACTS:
Jack Khattar, President & CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591